{"disease":{"id":"membranous-nephropathy","name":"membranous nephropathy"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06065852","title":"National Registry of Rare Kidney Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":35000,"lead_sponsor_name":"UK Kidney Association","has_results":false},{"nct_id":"NCT03929887","title":"KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT05839314","title":"Effect of Huaier Granule on the Treatment of Idiopathic Membranous Nephropathy","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":480,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false},{"nct_id":"NCT04326218","title":"Immunopathological Analysis in a French National Cohort of Membranous Nephropathy","phase":"NA","overall_status":"UNKNOWN","enrollment_count":400,"lead_sponsor_name":"Centre Hospitalier Universitaire de Nice","has_results":false},{"nct_id":"NCT04571658","title":"NEPTUNE Match Study","phase":"NA","overall_status":"RECRUITING","enrollment_count":375,"lead_sponsor_name":"University of Michigan","has_results":false},{"nct_id":"NCT06924476","title":"Optimization of a Decision Formula for Optimal Timing of Immunosuppressive Therapy Initiation in Primary Membranous Nephropathy: A Multicenter Retrospective Cohort Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":282,"lead_sponsor_name":"Yipeng Liu","has_results":false},{"nct_id":"NCT06470191","title":"A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy.","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":216,"lead_sponsor_name":"Shanghai Jiaolian Drug Research and Development Co., Ltd","has_results":false},{"nct_id":"NCT06893328","title":"A Real World Study About PMN","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Wei Chen","has_results":false},{"nct_id":"NCT06962800","title":"A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT07204275","title":"A Study to Evaluate Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":176,"lead_sponsor_name":"Vertex Pharmaceuticals Incorporated","has_results":false},{"nct_id":"NCT06614985","title":"The Efficacy and Safety of Treatment With Telitacicept in Primary Membranous Nephropathy","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":172,"lead_sponsor_name":"Renmin Hospital of Wuhan University","has_results":false},{"nct_id":"NCT07029139","title":"A Study to Learn More About the Effects and Safety of JMT601 in Adults With Primary Membranous Nephropathy","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":156,"lead_sponsor_name":"Shanghai JMT-Bio Inc.","has_results":false},{"nct_id":"NCT05505500","title":"Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.","phase":"","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"University of Michigan","has_results":false},{"nct_id":"NCT05696613","title":"A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":148,"lead_sponsor_name":"Cerium Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT07010250","title":"Epithelial Dysmetabolism and Renal Fibrosis in ANCA Vasculitis","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":146,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT06781944","title":"OBINOTUZUMAB Versus Cyclophosphamide + Glucocorticoids in Primary Membranous Nephropathy(Blossom Study)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":144,"lead_sponsor_name":"Huashan Hospital","has_results":false},{"nct_id":"NCT04629248","title":"A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":142,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT06642909","title":"A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous Nephropathy","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":135,"lead_sponsor_name":"BioRay Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT07404436","title":"Rivaroxaban in Idiopathic Membranous Nephropathy","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":134,"lead_sponsor_name":"Beijing Friendship Hospital","has_results":false},{"nct_id":"NCT05691179","title":"COVID-19 Infection and Idiopathic Membranous Nephropathy","phase":"","overall_status":"UNKNOWN","enrollment_count":130,"lead_sponsor_name":"Beijing Friendship Hospital","has_results":false},{"nct_id":"NCT03170323","title":"Mycophenolate Mofetil Plus Steroid in the Treatment Of Patients With Progressive Idiopathic Membranous Nephropathy","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":128,"lead_sponsor_name":"Guangdong Provincial People's Hospital","has_results":false},{"nct_id":"NCT06341205","title":"Personalized Rituximab Treatment Based on Artificial Intelligence in Membranous Nephropathy (iRITUX)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Centre Hospitalier Universitaire de Nice","has_results":false},{"nct_id":"NCT06573411","title":"Efficacy and Safety of Finerenone in Patients With Primary Membranous Nephropathy","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":116,"lead_sponsor_name":"First Affiliated Hospital, Sun Yat-Sen University","has_results":false},{"nct_id":"NCT06315504","title":"Circulating Factors in Nephrotic Syndrome","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":104,"lead_sponsor_name":"Iain Bressendorff","has_results":false},{"nct_id":"NCT05398653","title":"A Phase Ib/ Ⅱ Clinical Study of MIL62 in Primary Membranous Nephropathy","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":94,"lead_sponsor_name":"Beijing Mabworks Biotech Co., Ltd.","has_results":false},{"nct_id":"NCT03475602","title":"Membranous Nephropathy-associated Serological Antibody Predict the Prognosis of Idiopathic Membranous Nephropathy","phase":"","overall_status":"TERMINATED","enrollment_count":85,"lead_sponsor_name":"Guangdong Provincial People's Hospital","has_results":false},{"nct_id":"NCT01508468","title":"Evaluate Rituximab Treatment for Idiopathic Membranous Nephropathy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":80,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT05514015","title":"Clinical Study of Rituximab Combined With Corticosteroids or Rituximab Monotherapy in the Treatment of Primary Membranous Nephropathy","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":78,"lead_sponsor_name":"First Affiliated Hospital, Sun Yat-Sen University","has_results":false},{"nct_id":"NCT05732402","title":"An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":72,"lead_sponsor_name":"Alpine Immune Sciences, Inc.","has_results":false},{"nct_id":"NCT03804359","title":"Personalized Medicine for Membranous Nephropathy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":68,"lead_sponsor_name":"Centre Hospitalier Universitaire de Nice","has_results":false},{"nct_id":"NCT05136456","title":"Evaluate the Efficacy and Safety of SHR1459 Tablets in Patients With Primary Membranous Nephropathy","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":61,"lead_sponsor_name":"Reistone Biopharma Company Limited","has_results":false},{"nct_id":"NCT03949855","title":"Belimumab With Rituximab for Primary Membranous Nephropathy","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":58,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT02199145","title":"Role of Anti-mouse PLA2R1 ELISA in Membranous Nephropathy","phase":"NA","overall_status":"COMPLETED","enrollment_count":52,"lead_sponsor_name":"Centre Hospitalier Universitaire de Nice","has_results":false},{"nct_id":"NCT05668403","title":"A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":52,"lead_sponsor_name":"Shanghai Jiaolian Drug Research and Development Co., Ltd","has_results":false},{"nct_id":"NCT05688865","title":"Correlation and Clinical Utility of Urinary Biomarker in Membranous Glomerulonephritis","phase":"","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT06994468","title":"Effect of B-cell Depleting Therapies on PLA2R-specific B Cells in Patients With Membranous Nephropathy","phase":"NA","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"Mario Negri Institute for Pharmacological Research","has_results":false},{"nct_id":"NCT05894512","title":"Analysis of T- and B-Cell Subpopulations in Membranous Nephropathy","phase":"","overall_status":"COMPLETED","enrollment_count":44,"lead_sponsor_name":"Istanbul University","has_results":false},{"nct_id":"NCT05850845","title":"Study on the Application of Hyperspectral Imaging Technique in CTX Treatment of IMN","phase":"","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Qianfoshan Hospital","has_results":false},{"nct_id":"NCT05679336","title":"Rituximab, Cyclophosphamide, and Corticosteroids in Primary Membranous Nephropathy","phase":"NA","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"St. Petersburg State Pavlov Medical University","has_results":false},{"nct_id":"NCT05797038","title":"Study on the Application of Hyperspectral Imaging Technique in the Treatment of IMN by TAC","phase":"","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Qianfoshan Hospital","has_results":false},{"nct_id":"NCT04154787","title":"Efficacy and Safety of LNP023 Compared With Rituximab in Subjects With Idiopathic Membranous Nephropathy","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":37,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT07389499","title":"A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Grit Biotechnology","has_results":false},{"nct_id":"NCT05800873","title":"Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of EVER001","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Everest Medicines (China) Co.,Ltd.","has_results":false},{"nct_id":"NCT07157787","title":"Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT04733040","title":"Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R+ Membranous Nephropathy (aMN) (NewPLACE)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"HI-Bio, A Biogen Company","has_results":false},{"nct_id":"NCT06285279","title":"The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":24,"lead_sponsor_name":"Nanjing University School of Medicine","has_results":false},{"nct_id":"NCT04456816","title":"A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Treatment With AP1189 in Patients With iMN and Severe Proteinuria","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":23,"lead_sponsor_name":"SynAct Pharma Aps","has_results":false},{"nct_id":"NCT04278729","title":"A Prospective Multi-dose Study of Apixaban in Subjects With Nephrotic Syndrome","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":22,"lead_sponsor_name":"University of North Carolina, Chapel Hill","has_results":false},{"nct_id":"NCT03453619","title":"Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"Apellis Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT07163611","title":"Obinutuzumab Induced Decreases of PLA2R Antibodies in Membranous Nephropathy: a Pilot Study","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Radboud University Medical Center","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}